Scarica l'app Stockscreener
131.35
3.74%
4.74
Dopo l'orario di chiusura:
131.51
0.16
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$126.61
Aprire:
$127.17
Volume 24 ore:
8.14M
Relative Volume:
1.33
Capitalizzazione di mercato:
$227.80B
Reddito:
$41.95B
Utile/perdita netta:
$13.40B
Rapporto P/E:
17.17
EPS:
7.65
Flusso di cassa netto:
$6.35B
1 W Prestazione:
+3.60%
1M Prestazione:
-3.33%
6M Prestazione:
+16.83%
1 anno Prestazione:
+15.75%
Intervallo 1D:
$126.66
$131.93
Intervallo di 1 settimana:
$124.50
$131.93
Portata 52W:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
131.35 | 227.80B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.80 | 149.09B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
367.54 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.98 | 114.12B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.19 | 41.85B | 5.72B | 4.17B | 259.90M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott’s Volt enters the PFA fray with CE mark - BioWorld Online
Abbott Laboratories stock outperforms competitors on strong trading day - MSN
Abbott wins CE Mark for Volt PFA system to treat atrial fibrillation, begins EU rollout - Mass Device
Abbott Receives CE Mark for Pulsed Field Ablation System - Diagnostic and Interventional Cardiology
Oppenheimer maintains Abbott Labs target at $134 on CE Mark nod - Investing.com
Abbott accelerates PFA market competition in Europe with early Volt approval - Medical Device Network
Abbott's new AFib device gets early OK from European regulators - Crain's Chicago Business
BTIG maintains Buy on Abbott Labs stock, $140 target - Investing.com India
Abbott gains CE mark approval for Volt PFA system - Cardiovascular Business
Abbott Laboratories (ABT): Among Dividend Zombies to Invest in - Insider Monkey
Abbott’s Volt Pulsed Field Ablation Nabs EU Approval - MPO-mag
Abbott’s Volt PFA system gains CE Mark for AFib treatment By Investing.com - Investing.com Australia
Game-Changing Heart Treatment: Abbott's New AFib System Shows 99% Success in European Approval - StockTitan
Abbott India Finance Director Jyoti Saraph to resign - Medical Dialogues
Abbott Receives CE Mark For Its Volt(TM) Pulsed Field Ablation System To Treat Patients With Abnormal Heart Rhythms - Marketscreener.com
Diamond Hill Capital is Crazy About Abbott Laboratories (NYSE:ABT) - Insider Monkey
Behind the Scenes of Abbott Laboratories's Latest Options Trends - Benzinga
Abbott gets FDA nod to begin IVL trial after rivals buy up competition - MedTech Dive
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic - Yahoo Finance
Abbott Enters Intravascular Lithotripsy Market with FDA-Approved IDE - MD+DI
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Abbott makes IVL move as FDA approves new clinical trial - Cardiovascular Business
Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US - Simply Wall St
Abbott gets green light for clinical trials of new heart treatment system - Crain's Chicago Business
Abbott launches intravascular lithotripsy trial aimed at clearing coronary arteries - Fierce Biotech
Abbott Laboratories Gets FDA Approval to Assess Investigational Device in Heart Disease Clinical Trial - Marketscreener.com
TD Cowen maintains $135 target for Abbott Labs stock, reiterates Buy - Investing.com
Abbott is making an IVL play with FDA IDE nod - Mass Device
FDA approves Abbott’s CAD treatment trial - Investing.com India
Abbott Wins FDA IDE Nod for Coronary IVL Trial - MPO-mag
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Lateral Flow Assays Market Analysis Report 2025-2030: Next-generation LFAs, Advancement in LFA Solutions and Reagents, and Rising Acceptance of POC Testing - GlobeNewswire Inc.
Jim Cramer On Abbott Laboratories (ABT): “Abbott Labs Stock Is Back on My Radar” - Insider Monkey
Global Glucose Biosensor Market Positioned for Accelerated - openPR
Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up - Yahoo Finance
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock? - MSN
Abbott Settles Suit on HIV-Testing Patent With Novartis, Grifols - Bloomberg Law
What Does the Market Think About Abbott Laboratories?Abbott Laboratories (NYSE:ABT) - Benzinga
Abbott’s world-first portable whole blood rapid test for concussions launches in the UK (2) - PharmiWeb.com
U.S. Clinical Nutrition Market Is Booming Worldwide 2025-2032 | - openPR
Abbott (ABT) Gains But Lags Market: What You Should Know - Yahoo Finance
Medtronic, Abbott Block Boston Scientific Heart Valve IP - Law360
Abbott launches portable concussion blood test in UK - Medical Device Network
Abbott Laboratories: An Insight Into Its Medtech & Diagnostic Growth Trajectory & Why It May Not Be Enough To Warrant A ‘Buy’ Rating! - Smartkarma
Brazil Enteral Nutrition Market Is Booming Worldwide 2025-2032 - openPR
Medical Nutrition Market Key Players Analysis- Abbott - openPR
RFK Jr.’s Next Targets Are Companies Making Baby Formula - Yahoo Finance
US health agencies announce plan to strengthen infant formula supply and quality -March 18, 2025 at 02:23 pm EDT - Marketscreener.com
Abbott Laboratories (ABT): Among the Best Diabetes Stocks to Buy According to Billionaires - Insider Monkey
Decoding Abbott Laboratories's Options Activity: What's the Big Picture? - Benzinga
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Nasdaq
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.50%
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):